Filter This View

  • In re Geron Corp. Stockholder Derivative Litig.

    Publication Date: 2022-06-21
    Practice Area: Corporate Governance
    Industry: Biotechnology | Pharmaceuticals
    Court: Court of Chancery
    Judge: Vice Chancellor Glasscock
    Attorneys: For plaintiff: P. Bradford deLeeuw, deLeeuw Law LLC, Wilmington, DE; Kip B. Shuman, Shuman, Glenn & Stecker, San Francisco, CA; Rusty E. Glenn, Shuman, Glenn & Stecker, Denver, CO; Brett D. Stecker, Shuman, Glenn & Stecker, Ardmore, PA; Brian J. Robbins, Craig W. Smith, Shane P. Sanders, Emily R. Bishop, Robbins LLP, San Diego, CA; Richard A. Maniskas, RM Law, P.C., Berwyn, PA for plaintiffs.
    for defendant: D. McKinley Measley, Sarah P. Kaboly, Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE; Brett De Jarnette, John C. Dwyer, Cooley LLP, Palo Alto, CA; Ryan E. Blair, Cooley LLP, San Diego, CA for defendants.
    Case Number: D69855

    Although plaintiff shareholders' failure of oversight claim was likely to be subsumed by their fraudulent/misleading disclosure claim, the court stayed the action pending the outcome of a related securities action in another jurisdiction that would likely resolve genuine issues of material fact in the present case.

  • Maverick Therapeutics, Inc. v. Harpoon Therapeutics, Inc.

    Publication Date: 2021-05-12
    Practice Area: Mergers and Acquisitions
    Industry: Pharmaceuticals
    Court: Court of Chancery
    Judge: Vice Chancellor Glasscock
    Attorneys: For plaintiff: Jody C. Barillare, Morgan, Lewis & Bockius LLP, Wilmington, DE; Rollin B. Chippey II, Benjamin P. Smith, Morgan, Lewis & Bockius LLP, San Francisco, CA; John P. DiTomo, Elizabeth A. Mullin, Aubrey J. Morin, Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE; John Ruskusky, Lisa C. Sullivan, Nixon Peabody, LLP, Chicago, IL for plaintiffs.
    for defendant: Gregory P. Williams, Steven J. Fineman, Nicole K. Pedi, Angela Lam, Richards, Layton & Finger, P.A., Wilmington, DE; Martin S. Schenker, Lilia Lopez, Cooley LLP, San Francisco, CA; Jeffrey Karr, Cooley LLP, Palo Alto, CA for defendant.
    Case Number: D69392

    Purchaser of spin-off entitled to damages for fraudulent misrepresentation by seller who subsequently engaged in competition with spin-off, equal to both the half the value due to the splitting of the market and a further discount to reflect the seller's position as the pioneer of the technology that gave it a competitive advantage.

  • Maverick Therapeutics, Inc. v. Harpoon Therapeutics, Inc.

    Publication Date: 2020-04-22
    Practice Area: Contracts
    Industry: Investments and Investment Advisory | Pharmaceuticals
    Court: Court of Chancery
    Judge: Vice Chancellor Glasscock
    Attorneys: For plaintiff: : Jody C. Barillare, Morgan, Lewis & Bockius LLP, Wilmington, DE; Rollin B. Chippey II and Benjamin P. Smith, Morgan, Lewis & Bockius LLP, San Francisco, CA for plaintiff.
    for defendant: John P. DiTomo, Elizabeth A. Mullin, and Aubrey J. Morin, Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE; John Ruskusky and Lisa C. Sullivan, Nixon Peabody, LLP, Chicago, IL for plaintiff-Intervenor. Gregory P. Williams, Steven J. Fineman, Nicole K. Pedi, and Angela Lam, Richards, Layton & Finger, P.A., Wilmington, DE; Martin S. Schenker and Benjamin H. Kleine, of Cooley, LLP, San Francisco, CA; Michelle S. Rhyu, Cooley, LLP, Palo Alto, CA for defendant.
    Case Number: D68952

    Defendant fraudulently induced plaintiff's investment into spin-out company by representing broad definition of transferred technology while knowingly limiting transfer to the spin-off and continuing to work on technology outside the narrow definition.